$Anebulo Pharmaceuticals(ANEB.US)$Anebulo Pharmaceuticals Filed U.S. Patent Application #20240010617: Crystalline Forms Of A Cannabinoid Receptor Type 1 (Cb1) Modulator And Methods Of Use And Preparation Thereof
$Anebulo Pharmaceuticals(ANEB.US)$Anebulo Receives Positive Feedback From FDA On Path To Advance Phase 3 Clinical Development Of ANEB-001 And Completes Dosing Of Phase 2 Extension.
Anebulo Pharmaceuticals股票讨论区
Watching for answer
LIKE!
#phase 2
#phase 3 end of 2021
暂无评论